iBio, Inc.
IBIO
$2.22
$0.115.21%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 14.29% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 14.29% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | 14.29% | -- | -- |
| SG&A Expenses | 88.37% | -10.71% | -11.05% | 9.22% | -7.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 104.48% | 47.37% | 50.61% | 34.56% | 2.74% |
| Operating Income | -113.74% | -44.93% | -52.48% | -34.56% | 1.71% |
| Income Before Tax | -106.07% | -43.39% | -59.06% | -84.48% | 2.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -106.07% | -43.39% | -59.06% | -84.48% | 2.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -106.07% | -43.39% | 33.62% | -53.25% | 46.85% |
| EBIT | -113.74% | -44.93% | -52.48% | -34.56% | 1.71% |
| EBITDA | -120.15% | -47.07% | -56.61% | -38.63% | 0.89% |
| EPS Basic | 81.02% | 37.05% | 60.41% | 42.30% | 89.20% |
| Normalized Basic EPS | 81.02% | 37.05% | 5.16% | 49.65% | 80.24% |
| EPS Diluted | 81.02% | 37.05% | 60.41% | 42.32% | 89.20% |
| Normalized Diluted EPS | 81.02% | 37.05% | 5.16% | 49.65% | 80.24% |
| Average Basic Shares Outstanding | 985.56% | 127.80% | 67.66% | 165.61% | 392.03% |
| Average Diluted Shares Outstanding | 985.56% | 127.80% | 67.66% | 165.61% | 392.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |